Table 1.

Patient and treatment characteristics

Patient characteristicsBiopsy
• Age• Time until PET scan
• Sex• HistologyErlotinib therapy
Patient• Smoking status• IHC• TKI before PET scana
Groupnumber• EthnicityStage (TNM)• EGFR DNA sequencing• TKI after PET scanb
11• 61IIIb (cT4Nx-2M0)• 20 d• NA
• Male• ASC• NA
• Former smoker• +++
• Caucasian• Wild-type
12• 57IIIb (cT4Nx-2M0)• 4 mo after PET scan• NA
• Male• SCC• NA
• Former smoker• +++
• Caucasian• Wild-type
13• 59IV (cT4N2M1a)• 20 mo• 2 mo/PD/3 mo
• Female• AC• NA
• Former smoker• +++
• Caucasian• Wild-type
14• 46IV (cT4N2M1a)• 16 mo• 4 mo/PD/41 mo
• Female• AC• NA
• Never smoker• ++
• African• Wild-type
15• 65IV (rT2aN1M1a)• 28 mo• NA
• Male• AC• NA
• Former smoker• +++
• Caucasian• Exon 19 wild-type; exon 20 insertion (D770–N771 (ins GG) + N771T)
26• 46IIIb (cT4N3M0)• 13 d• NA
• Female• AC• 18 mo/PR/1 d
• Never smoker• +++
• Asian• Exon 19 deletion (del E746–A750)
27• 47IV (cT3N0M1a)• 1 mo• 19 mo/PR/4 mo
• Male• AC• 20 moc/PR/3 wk
• Never smoker• +++
• Asian• Exon 19 deletion (del L747–T751)
28• 51IV (T2aN3M1b)• 6 d• First episoded: 11 mo/PR
• Female• ASC• Second episode: 3 mo/PD/3 wk
• Never smoker• +++• NA
• Caucasian• Exon 19 deletion (del E746–A750)
29• 37IIa (rT1N1M0)• 10 mo• NA
• Female• AC• NAe
• Never smoker• +++
• Caucasian• Exon 19 deletion (del E746–A750)
210• 54IV (T4N0M1a)• 12 mo• 18 mo/PR/11 mo
• Female• AC• 4 mo/PR/1 d
• Never smoker• +++
• Caucasian• Exon 19 deletion (del E746–A750)

NOTE: Patients were categorized into 2 groups, according to the presence of activating mutations. Disease stage is indicated using the IASLC classification, 7th edition (25). Using IHC, EGFR protein expression was visually scored as high (+++), moderate (++), or low (+; ref. 19). EGFR mutational status was assessed by DNA sequencing on tumor biopsies (11, 12).

Abbreviations: AC, adenocarcinoma; ASC, adenosquamous carcinoma; NA, not applicable; PD, progressive disease; PR, partial response; SCC, squamous cell carcinoma.

  • aErlotinib therapy duration, best response, and TKI-free period for patients treated before scanning are shown.

  • bTreatment duration, best response. and start date of erlotinib for patients treated after scanning are shown. Best response to TKI therapy prior and after scanning was scored according to RECIST (20).

  • cPatient 7 is progression free to date, that is, 22 months and ongoing.

  • dPatient 8 was treated twice with erlotinib: in a first episode, she achieved partial response, but treatment was discontinued after 11 months due to disease progression. Six months after discontinuation she was retreated with erlotinib, this time she did not achieve tumor response.

  • ePatient 9 was treated with chemoradiation, not with TKI, as this patient had only local disease.